GlassScriptPhysician profile
Alejandro Francisco Centurion
NPI 1184739757
$1,041.29
in general payments reported to CMS, 2019-2025
14 companies · $275 in 2025
The $275 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $270 · 2021: $276 · 2022: $34.36 · 2023: $44.80 · 2024: $29.95 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $334 · Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $334.40 |
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $304.82 | 2021-2025 | Duopa, Vraylar |
| Ucb, INC. | $175.64 | 2020-2025 | Rystiggo |
| Acorda Therapeutics, INC | $93.76 | 2019 | |
| Boston Scientific Corporation | $82.77 | 2021 | |
| Allergan, INC. | $75.73 | 2019-2021 | |
| Lundbeck LLC | $67.78 | 2024-2025 | Vyepti, Rexulti |
| Sk Life Science, INC. | $66.00 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $41.82 | 2020 | |
| Kyowa Kirin, INC. | $32.03 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $29.77 | 2020 | |
| Impel Pharmaceuticals INC. | $27.06 | 2022-2023 | Trudhesa |
| Emd Serono, INC. | $16.11 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.35 | 2021 | |
| Biogen, INC. | $13.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Centurion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.